1-3 of 3
Authors: Samuel Blackman
Journal Article
CTNI-30. LOGGIC/FIREFLY-2: A PHASE 3, RANDOMIZED TRIAL OF TOVORAFENIB VS. CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED LOW-GRADE GLIOMA HARBORING AN ACTIVATING RAF ALTERATION
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Pages vii77–vii78, https://doi.org/10.1093/neuonc/noac209.295
Published: 14 November 2022
Journal Article
CTNI-68. FIREFLY-1 (PNOC026): PHASE 2 STUDY OF PAN-RAF INHIBITOR TOVORAFENIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RAF-ALTERED RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA OR ADVANCED SOLID TUMORS
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii89, https://doi.org/10.1093/neuonc/noac209.333
Published: 14 November 2022
Journal Article
BIOM-37. INITIAL RADIOGRAPHIC ASSESSMENT OF ADC VALUES IN PEDIATRIC PATIENTS TREATED WITH DAY101 FOR RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMAS (LGGs) HARBORING MEK/ERK PATHWAY ALTERATIONS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii9, https://doi.org/10.1093/neuonc/noaa215.036
Published: 09 November 2020
